James W Lynch

James W Lynch, M.D.

Professor And Assistant Dean

Department: MD-HEMATOLOGY/ONCOLOGY
Business Phone: (352) 273-7832
Business Email: lynchjw@ufl.edu

About James W Lynch

Dr. Lynch received his BA from the University of Virginia and MD from Eastern VA Medical School in 1984. After internal medicine training at the University of Florida, he did his training in medical oncology at the National Cancer Institute in Bethesda MD. In 1991 he returned to the UFCOM and has served in multiple roles during this tenure including, course director in Oncology (20 years), program director for hematology/oncology (13 years), section chief of hematology/oncology at the VAMC and now serves as the Assistant Dean for Admissions. He is a nationally recognized well published expert in the diagnosis and treatment of lymphomas and has coauthored over 130 papers, book chapters and abstracts. His educational roles include teaching cancer biology, clinical oncology, clinical reasoning and humanism in medicine. He was the first faculty inductee into the Chapman Humanism Society at the UFCOM and serves on its board of directors. He has received multiple teaching awards including clinical teacher of the year 5 times, the Hippocratic award three times, is a member of the College of Medicine Society of Teaching Scholars and in 2006 was honored by the University of Florida as one of 5 Distinguished Teaching Scholars. He was co-founder with his wife of the Christian Study Center at the University of Florida and serves as its board president. He and his wife Laura, have 4 children and 3 grandchildren.

Teaching Profile

Courses Taught
2013-2018,2020-2024
BMS6816 Cancer Bio Clin Oncol
2020-2024
BMS6631 Hematology
2018
MDC7200 Medicine Clerkship
2018
MDC6001 Intro Clin Practice
2015,2018
BMS6638C Kidney & Urinary Tract
2013,2018
MDT7200 Elect Top/Medicine
2010-2013
MEL7948 Elect Top/Medicine
2011-2012
BMS6630 Clinical Oncology

Board Certifications

  • Internal Medicine
    American Board of Internal Medicine
  • Oncology
    American Board of Internal Medicine

Clinical Profile

Specialties
  • Cancer
  • Hematology and Oncology
Areas of Interest
  • Lymphoma

Publications

2022
Establishing Cost-Effective Allocation of Proton Therapy for Patients With Mediastinal Hodgkin Lymphoma.
International journal of radiation oncology, biology, physics. 112(1):158-166 [DOI] 10.1016/j.ijrobp.2021.07.1711. [PMID] 34348176.
2018
How Bureaucracy Can Foster Burnout.
Journal of the American College of Radiology : JACR. 15(12):1803-1805 [DOI] 10.1016/j.jacr.2018.06.015. [PMID] 30145118.
2018
Radiotherapy for extranodal classic Hodgkin lymphoma of the maxillary sinus: Case report and literature review.
Head & neck. 40(9):E96-E99 [DOI] 10.1002/hed.25346. [PMID] 30051529.
2017
The Man in the Vest.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(35):3987-3988 [DOI] 10.1200/JCO.2017.75.1321. [PMID] 28985101.
2016
Medical educational culture: introducing patients to applicants as part of the medical school interview: feasibility and initial impact show and tell.
Medical education online. 21 [DOI] 10.3402/meo.v21.31760. [PMID] 27520404.
2015
Proton therapy in the management of non-Hodgkin lymphoma.
Leukemia & lymphoma. 56(9):2608-12 [DOI] 10.3109/10428194.2015.1014364. [PMID] 25669925.
2014
Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study.
International journal of radiation oncology, biology, physics. 89(5):1053-1059 [DOI] 10.1016/j.ijrobp.2014.04.029. [PMID] 24928256.
2013
Phase 2 Study of Consolidative Involved-Node Proton Therapy in Patients With Hodgkin Lymphoma: Early Outcomes
International Journal of Radiation Oncology Biology Physics. 87:S162-S163
2012
Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.
International journal of radiation oncology, biology, physics. 83(1):260-7 [DOI] 10.1016/j.ijrobp.2011.06.1959. [PMID] 22014950.
2012
Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma.
International journal of radiation oncology, biology, physics. 84(2):449-55 [DOI] 10.1016/j.ijrobp.2011.12.034. [PMID] 22386373.
2012
Improving the Therapeutic Ratio in Hodgkin Lymphoma Through the Use of Proton Therapy
Oncology. 26:456-465
2012
Outcomes of patients with non-Hodgkin’s lymphoma treated with Bexxar with or without external-beam radiotherapy.
International journal of radiation oncology, biology, physics. 82(3):1122-7 [DOI] 10.1016/j.ijrobp.2010.09.044. [PMID] 21570217.
2010
Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
The journal of supportive oncology. 8(2):72-7 [PMID] 20464886.
2009
Long-term outcomes for stage I-II aggressive non-Hodgkin lymphoma of Waldeyer’s ring.
American journal of clinical oncology. 32(3):233-7 [DOI] 10.1097/COC.0b013e318187ddbb. [PMID] 19433961.
2008
Tumor-Associated S-Phase Fraction Correlates With the Presence of C-Myc Translocation in Aggressive Cd10-Expressing B-Cell Lymphomas and May Predict Their Clinical Course
Modern Pathology. 21
2008
Tumor-Associated S-Phase Fraction Correlates With the Presence of C-Myc Translocation in Aggressive Cd10-Expressing B-Cell Lymphomas and May Predict Their Clinical Course
Modern Pathology. 21
2008
Tumor-Associated S-Phase Fraction Correlates With the Presence of C-Myctranslocation in Aggressive Cd10-Expressing B-Cell Lymphomas and May Predict Their Clinical Course
Modern Pathology. 88
2007
Clinical presentation and outcomes of lymphocyte-predominant Hodgkin disease at the University of Florida.
American journal of clinical oncology. 30(6):601-6 [PMID] 18091054.
2007
Discordant expression of CD20 by flow cytometry and immunohistochemistry in a patient responding to rituximab: an unusual mechanism.
Clinical lymphoma & myeloma. 7(4):319-22 [PMID] 17324342.
2006
Lethal midline granuloma-nasal natural killer/T-cell lymphoma.
American journal of clinical oncology. 29(2):202-6 [PMID] 16601443.
2005
A phase II study of gemcitabine in patients with relapsed or refractory low-grade non-Hodgkin lymphoma.
American journal of clinical oncology. 28(2):165-8 [PMID] 15803011.
2005
Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(6):1096-102 [PMID] 15657402.
2005
Potential influence of health systems in accrual to clinical trials in lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(28):7244-5 [PMID] 16192620.
2004
Paraneoplastic manifestations of lymphoma.
Clinical lymphoma. 5(1):29-36 [PMID] 15245605.
2003
Management of neurotropic low-grade B-cell lymphoma: report of two cases.
Head & neck. 25(11):972-6 [PMID] 14603459.
2002
Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults.
American journal of clinical oncology. 25(5):489-95 [PMID] 12393991.
2002
Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-hodgkin’s lymphoma.
American journal of clinical oncology. 25(4):391-7 [PMID] 12151972.

Grants

Jul 2006 – Dec 2020
21st Century Research & Economic Development Investment Program (REDIP)
Role: Project Manager
Funding: STATE UNIV SYS OF FL BOARD OF GOVERNORS

Education

Residency – Internal Medicine
1987 · University of Florida
Internship – Internal Medicine
1985 · University of Florida
Medical Degree
1984 · Eastern Virginia Medical School

Contact Details

Phones:
Business:
(352) 273-7832
Emails:
Business:
lynchjw@ufl.edu
Addresses:
Business Mailing:
PO Box 100278
GAINESVILLE FL 32610
Business Street:
Admissions Office
1104 Newell Drive Room 142
Harrell Medical Education Building
GAINESVILLE FL 32610